Regulatory innovations: why is the UK an attractive hub for CGT development?

“...the UK has representation in nearly 50% of all European ATMP trials”

Jokūbas Leikauskas, Editor, BioInsights, speaks to Rehma Chandaria, Senior Regulatory Affairs Lead, Cell and Gene Therapy Catapult, about the UK’s position as an attractive hub for cell and gene therapy (CGT) development, recent Medicines and Healthcare products Regulatory Agency (MHRA) initiatives reshaping the regulatory framework, and the global implications of post-Brexit regulatory divergence.

Please enter your email to access content Read now